Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
$1.34
-4.0%
$1.28
$0.77
$2.63
$110.34M1.04222,513 shs120,980 shs
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
$2.47
-1.0%
$3.02
$1.80
$7.93
$107.67M0.17262,006 shs37,806 shs
MariMed Inc. stock logo
MRMD
MariMed
$0.10
+2.5%
$0.08
$0.07
$0.29
$40.22M2.9404,417 shs130,194 shs
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$1.51
-1.6%
$1.74
$0.82
$3.10
$119.81M-0.23583,306 shs81,701 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
-0.71%0.00%-3.47%+55.13%-26.84%
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
+0.40%-4.60%-13.54%-35.66%+248,999,900.00%
MariMed Inc. stock logo
MRMD
MariMed
+15.38%+17.68%+41.95%+27.22%-41.91%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
+3.38%+2.00%-0.65%-33.77%+41.67%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
1.8944 of 5 stars
3.73.00.00.00.60.00.6
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
1.2226 of 5 stars
3.70.00.00.00.80.00.0
MariMed Inc. stock logo
MRMD
MariMed
0.2728 of 5 stars
0.03.00.00.00.00.80.6
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
2.3486 of 5 stars
3.53.00.00.00.00.01.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
3.33
Buy$8.00475.54% Upside
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
3.40
Buy$12.67408.70% Upside
MariMed Inc. stock logo
MRMD
MariMed
4.00
Strong BuyN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
3.00
Buy$15.00880.39% Upside

Current Analyst Ratings Breakdown

Latest MRMD, PLX, HURA, and CRDL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2025
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/2/2025
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$9.00
5/16/2025
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
4/16/2025
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
N/AN/AN/AN/A$0.22 per shareN/A
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/AN/AN/AN/A$0.34 per shareN/A
MariMed Inc. stock logo
MRMD
MariMed
$157.96M0.25$0.02 per share4.04$0.16 per share0.63
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$59.76M2.04$0.09 per share17.80$0.47 per share3.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
-$26.77M-$0.34N/AN/AN/AN/A-209.63%-141.09%7/14/2025 (Estimated)
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
-$21.68MN/A0.00N/AN/A291.69%122.09%N/A
MariMed Inc. stock logo
MRMD
MariMed
-$12.16M-$0.03N/AN/A-10.33%-10.21%-3.12%8/6/2025 (Estimated)
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$8.31M$0.04N/A4.94N/A-21.03%-30.89%-11.74%N/A

Latest MRMD, PLX, HURA, and CRDL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
MariMed Inc. stock logo
MRMD
MariMed
-$0.01N/AN/AN/A$40.80 millionN/A
5/15/2025Q1 2025
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
-$0.13-$0.15-$0.02-$0.15N/AN/A
5/9/2025Q1
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/A-$0.05N/AN/AN/AN/A
5/7/2025Q1 2025
MariMed Inc. stock logo
MRMD
MariMed
-$0.01-$0.01N/A-$0.01$38.33 million$37.96 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
N/AN/AN/AN/AN/A
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/AN/AN/AN/AN/A
MariMed Inc. stock logo
MRMD
MariMed
N/AN/AN/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
0.01
3.26
3.26
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/A
3.00
3.00
MariMed Inc. stock logo
MRMD
MariMed
1.21
1.05
0.37
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/A
1.98
1.27

Institutional Ownership

CompanyInstitutional Ownership
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
12.49%
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
0.62%
MariMed Inc. stock logo
MRMD
MariMed
0.18%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
16.53%

Insider Ownership

CompanyInsider Ownership
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
5.25%
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
0.20%
MariMed Inc. stock logo
MRMD
MariMed
18.99%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
6.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
2082.65 million78.31 millionNot Optionable
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/A43.68 million43.59 millionN/A
MariMed Inc. stock logo
MRMD
MariMed
260390.44 million316.29 millionNot Optionable
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
20079.61 million69.00 millionOptionable

Recent News About These Companies

PLX: First Quarter Results
Protalix Stock (PLX) Grabbing Attention with Record Revenue Surge

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cardiol Therapeutics stock logo

Cardiol Therapeutics NASDAQ:CRDL

$1.34 -0.06 (-3.96%)
As of 10:36 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

TuHURA Biosciences stock logo

TuHURA Biosciences NASDAQ:HURA

$2.48 -0.01 (-0.60%)
As of 10:36 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

MariMed stock logo

MariMed OTCMKTS:MRMD

$0.10 +0.00 (+2.49%)
As of 09:57 AM Eastern

MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty's Eddies brand and ice creams under Emack & Bolio's brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.

Protalix BioTherapeutics stock logo

Protalix BioTherapeutics NYSE:PLX

$1.50 -0.03 (-1.63%)
As of 10:36 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.